Printer Friendly

UNIMED SIGNS LICENSE AGREEMENT FOR DISTRIBUTION OF MARINOL IN SOUTH KOREA

             UNIMED SIGNS LICENSE AGREEMENT FOR
           DISTRIBUTION OF MARINOL IN SOUTH KOREA
    SOMERVILLE, N.J., Nov. 1 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today the signing of a licensing and supply agreement with Keun Wha Pharmaceutical Co., Ltd. of Seoul for the distribution of Marinol(R) (dronabinol) in South Korea.  Under the terms of the agreement Keun Wha will initiate and fund certain clinical work, will obtain product registration in South Korea, will pay UNIMED a licensing fee upon registration and will purchase its Marinol requirements from UNIMED.
    Keun Wha is a leading supplier of pharmaceuticals in the infectious disease market in South Korea.  It has established alliances with leading international pharmaceutical companies including Warner-Lambert (U.S.), Fujisawa (Japan) and Bayer (Germany).
    Harold J. Tenoso, Ph.D., UNIMED's chairman and chief executive officer, said, "UNIMED is delighted to be collaborating with Keun Wha and to be entering into its first Asian alliance with Marinol.  We are negotiating with other potential overseas partners and hope to announce the signing of additional agreements in coming months."
    Marinol is UNIMED's antinausea pharmaceutical for the treatment of cancer chemotherapy patients.  It is currently undergoing clinical trials for appetite stimulation and prevention of weight loss in AIDS patients.  The FDA has granted Marinol Orphan Drug designation for this use.
     UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer and AIDS patients.  The company has brought two pharmaceuticals to market and has a portfolio of drugs in development.
    -0-          11/1/91
    /CONTACT:  Charles P. Harrison, president of UNIMED, 908-526-6894/
    (UMED) CO:  UNIMED, Inc.; Keun Wha Pharmaceutical Co., Ltd. ST:  New Jersey IN:  MTC SU:  LIC PS -- NY002 -- 0091 11/01/91 09:27 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1991
Words:288
Previous Article:WENDY'S RESPONDS TO SHAREHOLDER CONCERNS
Next Article:MARKET-LEADING MIDWEST APPLIANCE AND ELECTRONICS CHAIN TO SELL WANG EXEC SERIES PCS
Topics:


Related Articles
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
UNIMED ANNOUNCES APPROVAL OF MARINOL EFFICACY SUPPLEMENT BY FOOD AND DRUG ADMINISTRATION
UNIMED PHARMACEUTICALS LICENSES BROAD SPECTRUM, ANTI-INFECTIVE DRUG; INITIAL FOCUS ON TREATING INFECTION IN AIDS PATIENTS
UNIMED PHARMACEUTICALS LICENSES TESTOSTERONE PRODUCTS
UNIMED INTRODUCES MARINOL IN AUSTRALIA AND PUERTO RICO
UNIMED PHARMACEUTICALS TO DEVELOP SERC FOR VERTIGO IN THE UNITED STATES; RECEIVES $1.4 MILLION IN PAYMENTS
Unimed Announces Approval And Launch Of Marinol In South Africa
Par Pharmaceutical Announces Agreement With Unimed Pharmaceuticals to Settle AndroGel(R) Patent Litigation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters